The Global Lupus Therapeutic Market is estimated to be valued at US$ 3035.59 Mn or Bn in 2023 and is expected to exhibit a CAGR of 8.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Lupus is an autoimmune disease where the body’s immune system attacks its own tissues and organs. Lupus therapeutics are used to treat symptoms of lupus and manage the disease. They include corticosteroids, antimalarials, immunosuppressants and biologics.
Market key trends:
Increasing prevalence of lupus globally is a major factor driving the growth of the market. According to Lupus Foundation of America, nearly 1.5 million Americans and at least 5 million people worldwide have a form of lupus. Drug development for new indications is also contributing to the market growth. For instance, drugs initially approved for other autoimmune conditions like rheumatoid arthritis are now being explored for lupus treatment as well. Growing awareness about lupus diagnosis and management through patient advocacy groups is another key trend in the market.
Market Key Trends:
The Lupus therapeutic market is witnessing high research and development activities focused on developing novel therapeutics to treat lupus. Advancements in understanding the disease pathogenesis combined with growing focus on precision medicine is expected to bring more targeted and effective treatments. Biologics have emerged as an important treatment option and drugs targeting B-cell mediated immunity such as belimumab have shown promise. Additionally, pipeline drugs targeting type I interferons and IL-17 are progressing well and if approved can make a significant impact.
SWOT Analysis:
Strength: Growing prevalence of lupus globally is driving the demand for effective treatment options.
Weakness: High failure rate of drug candidates and lack of approved drugs for organ-specific lupus limit the treatment options available.
Opportunity: Advancements in understanding disease pathogenesis and emerging therapeutic classes like biologics/biosimilars provide scope for novel targeted therapies.
Threats: Stringent regulations for drug approval and high development cost poses challenges especially for small companies.
Key Takeaways
The Global Lupus Therapeutic Market is expected to witness high growth, exhibiting CAGR of 8.6% over the forecast period, due to increasing research and development activities focused on developing novel targeted therapies.
Regional analysis: North America dominated the lupus therapeutic market in 2023 due to availability of reimbursement and presence of major players. However, Asia Pacific is anticipated to grow at the fastest pace owing to rising lupus patient pool and improved access to diagnosis and treatment.
Key players operating in the Lupus therapeutic market are Hikma Pharmaceuticals PLC, Lupus Therapeutics, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., ADMA Biologics, Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
